Study of New Cardiac Biomarkers and Risk Scores to Diagnose Acute Myocardial Infarction and Acute Coronary Syndrome

What this Trial Is About

Researchers are investigating new cardiac biomarkers and algorithms to improve the diagnosis of acute coronary syndrome ACS in people who may be experiencing an acute myocardial infarction, which is a type of heart attack. The study also aims to enhance ACS risk scores by including clinical, gender-specific, psychosocial, lifestyle factors, protein patterns, and genetic variability alongside traditional risk factors. This observational study also explores the impact of socio-economic factors on ACS and coronary artery disease risk. Participants are patients who have recently developed symptoms suggesting an acute myocardial infarction. During their hospital stay, researchers will collect data and samples such as DNA, RNA, cells, and blood plasma to perform genetic, gene expression, and proteomic studies. The study will also use genome-wide analyses to identify new therapeutic targets and examine the role of candidate genes for ACS. Participants will be followed during their hospital stay and then contacted by telephone for follow-up at 30 days, 6 months, 24 months, and 48 months after the event. Researchers will measure the occurrence of acute myocardial infarction as the primary outcome and will also track mortality, heart failure, and quality of life over several years. This long-term follow-up helps to better understand ACS and its precursors.

Biomarkers in Acute Cardiac Care